apixaban (Rx)

Brand and Other Names:Eliquis
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 2.5mg
  • 5mg
more...

Stroke Prophylaxis with Atrial Fibrillation

Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation

5 mg PO BID

Postoperative Prophylaxis of DVT/PE

Indicated following hip or knee replacement surgery

Initial: Give 2.5 mg PO 12-24 hr after surgery

Duration of therapy (hip replacement): 2.5 mg PO BID for 35 days

Duration of therapy (knee replacement): 2.5 mg PO BID for 12 days

Renal impairment, including with ESRD on dialysis

  • Deep Vein Thrombosis: No dose adjustment recommended; clinical efficacy and safety studies did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-FXa activity) data in study subjects with ESRD maintained on dialysis

DVT or PE Treatment

Indicated for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE)

10 mg PO BID x 7 days, then 5 mg BID

Reduce risk for recurrent DVT or PE

  • Indicated to reduce the risk of recurrent DVT and PE following initial 6 months treatment for DVT and/or PE
  • 2.5 mg PO BID

Renal impairment, including with ESRD

  • No dose adjustment recommended; clinical efficacy and safety studies did not enroll patients with ESRD on dialysis or patients with a CrCl <15 mL/min; dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-FXa activity) data in study subjects with ESRD maintained on dialysis

Dosage Modifications

Coadministration with dual inhibitors of CYP3A4 and P-gp

  • If taking >2.5 PO BID, decrease dose by 50%
  • If taking 2.5 mg BID, avoid coadministration with strong dual inhibitors

Nonvalvular atrial fibrillation

  • Decrease dose to 2.5 mg PO BID in patients with any 2 of the following characteristics:
  • Age ≥80 years
  • Weight ≤60 kg
  • Serum creatinine ≥1.5 mg/dL

Renal impairment (nonvalvular atrial fibrillation)

  • Mild-to-moderate: No dosage adjustment required
  • Serum creatinine ≥1.5 mg/dL: Decrease dose to 2.5 mg BID if patient has 1 additional characteristic of age ≥80 years or weight ≤60 kg
  • ESRD maintained on hemodialysis: 5 mg BID; decrease dose to 2.5 mg BID if 1 additional characteristic of age ≥80 years or weight ≤60 kg is present

Hepatic impairment

  • Mild: No dosage adjustment required
  • Moderate: Patients may have intrinsic coagulation abnormalities; data are limited and no recommendations are available
  • Severe: Not recommended

Dosing Considerations

Switching between apixaban and anticoagulants other than warfarin: Discontinue one being taken, and begin the other at the next scheduled dose

Switching from warfarin to apixaban: Discontinue warfarin and initiate apixaban when INR <2.0

Switching from apixaban to warfarin

  • Apixaban affects INR, so measurements during coadministration with warfarin may not determine appropriate warfarin dose
  • If continuous anticoagulation is necessary, discontinue apixaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of apixaban would have been taken
  • Discontinue parenteral anticoagulant when INR reaches an acceptable level

Surgery/procedures

  • Discontinue at least 48 hr before elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding
  • Discontinue at least 24 hr before elective surgery or invasive procedures with a low risk of unacceptable or where the bleeding would be noncritical in location and easily controlled

Administration

May take with or without food

Missed dose: If not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice daily administration should be resumed; do not double the dose to make up for a missed dose

For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg tablets may be crushed and suspended in water, 5% dextrose in water (D5W), or apple juice, or mixed with applesauce and promptly administered orally; alternatively, tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a nasogastric tube; crushed tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hr

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and apixaban

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Bleeding (Aristotle Study)

            Major (2.13%, warfarin 3.09%; P <0.0001)

            GI (0.83%, warfarin 0.93%)

            Intracranial (0.33%, warfarin 0.82%)

            Intraocular (0.06%, warfarin 0.14%)

            Fatal (0.06%, warfarin 0.24%)

            Clinically relevant nonmajor bleeding (2.08%, warfarin 3.0%; P <0.0001)

            Bleeding (Averroes Study)

            Major (1.41%, aspirin 0.92%; P = 0.07)

            Fatal (0.16%, aspirin 0.16%)

            Intracranial (0.34%, aspirin 0.35%)

            <1%

            Hypersensitivity reactions (including skin rash and anaphylactic reactions such as allergic edema)

            Syncope

            Previous
            Next:

            Warnings

            Black Box Warnings

            Discontinuing in patients with nonvalvular atrial fibrillation

            • Premature discontinuation of any oral anticoagulant, including, apixaban, increases risk of thrombotic events; consider using another anticoagulant if anticoagulation with apixaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy
            • An increased rate of stroke was observed following discontinuation of apixaban in clinical trials in patients with nonvalvular atrial fibrillation
            • If anticoagulation with apixaban must be discontinued for a reason other than pathological bleeding, coverage with another anticoagulant should be strongly considered (see Dosing Considerations)

            Spinal/epidural hematoma

            • Increased risk of epidural or spinal hematoma when used with neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture (can result in long-term or permanent paralysis)
            • Risk increased with indwelling epidural catheters for administration of analgesia or by the concomitant use of drugs affecting hemostasis (eg, NSAIDs, platelet aggregation inhibitors, other anticoagulants)
            • Risk also increased by traumatic or repeated epidural or spinal puncture; if this occurs, delay apixaban administration for 48 hr
            • Monitor patients for signs and symptoms of neurologic impairment; if neurologic compromise is noted, urgent treatment is necessary
            • Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hr after the last administration of apixaban; the next apixaban dose should not be administered earlier than 5 hr after the removal of the catheter
            • Consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis

            Contraindications

            Severe hypersensitivity (ie, anaphylactic reactions)

            Active pathological bleeding

            Cautions

            Discontinuing apixaban in the absence of adequate alternative anticoagulation increases the risk of thrombotic events (see Black Box Warnings)

            Risk of epidural or spinal hematoma when used with neuraxial anesthesia (see Black Box Warnings)

            Safety and efficacy has not been studied in patients with prosthetic heart valves; therefore, use of is not recommended in these patients

            Not recommended as an alternative to unfractionated heparin for the initial treatment of PE in patients who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy

            Coadministration with strong dual inhibitors of CYP3A4 and P-gp (see Dosage Modifications)

            Avoid coadministration with strong dual inducers of CYP3A4 and P-gp; such drugs decrease apixaban’s systemic exposure

            Increases the risk of bleeding and can cause serious, potentially fatal, bleeding

            Coadministration with other drugs that affect hemostasis increases bleeding risk (eg, aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, NSAIDs)

            Prolongs PT and aPTT; however, changes are small and highly variable and are not useful for monitoring anticoagulation effect of apixaban

            Reversing apixaban effect

            • No specific antidote is available to reverse anticoagulant effect, which is expected to persist for about 24 hr after the last dose (~2 half-lives)
            • Because of high plasma protein binding, apixaban is not expected to be dialyzable
            • Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban
            • There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban
            • There is neither scientific rationale for reversal nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban
            • Use of procoagulant reversal agents (eg, prothrombin complex concentrate, activated prothrombin complex concentrate, or recombinant factor VIIa) may be considered but has not been evaluated in clinical studies
            • Activated oral charcoal reduces absorption of apixaban, thereby lowering plasma concentration
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B; increased incidence of maternal bleeding, primarily during gestation when studied in rats

            Lactation: Unknown whether distributed in human breast milk; rats excreted apixaban in milk (12% of the maternal dose)

            Women should be instructed either to discontinue breastfeeding or to discontinue apixaban therapy, taking into account the importance of the drug to the mother

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Factor Xa inhibitor that inhibits platelet activation by selectively and reversibly blocking the active site of factor Xa without requiring a cofactor (eg, antithrombin III) for activity

            Inhibits free and clot-bound factor Xa, and prothrombinase activity; no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin

            Blood coagulation cascade is dependent on the activation of factor X to factor Xa via the intrinsic and extrinsic pathways, which play a central role in the blood coagulation cascade

            Absorption

            Bioavailability: Displays prolonged absorption Peak Plasma Concentration: 3-4 hr

            Distribution

            Protein Bound: 87%

            Vdss: 21 L

            Metabolism

            Metabolized mainly by CYP3A4

            Metabolized with minor contributions from CYP1A2, 2C8, 2C9, 2C19 and 2J2

            Major sites of biotransformation: O-demethylation and hydroxylation at the 3-oxopirperidinyl moiety

            Metabolites: No active circulating metabolites Substrate of P-gp and BCRP

            Elimination

            Half-life: 5-6 hr (dominant); 12 hr (apparent half-life with repeated dosing)

            Dialyzable: No

            Renal clearance: 27%

            Excretion: 25% in urine and feces as metabolites; renal excretion accounts for 27% of total clearance; biliary and direct intestinal excretion contributes to elimination in feces

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous